​COVID-19 (Coronavirus): Infusion drug treatment

May 18, 2021

This article was revised on May 18, 2021, to update the list of covered drugs.

AmeriHealth will cover the use of several infusion drugs (and drug combinations) to treat members who have been diagnosed with COVID-19.

  • Bamlanivimab® (LY-CoV555) in combination with Etesevimab® (LY-CoV016
  • Casirivimab/Imdevimab
  • Veklury® (remdesivir) (including in combination with Olumiant® [baricitinib])

These drugs (and drug combinations) must be administered under supervision of a clinical professional. Drug administration in a setting consistent with that required by the FDA’s Emergency Use Authorization allows the clinician to monitor and treat infusion reactions like anaphylaxis.

AmeriHealth is committed to providing our members with access to the care they need during the COVID-19 pandemic. We encourage all AmeriHealth members and providers to visit our dedicated AmeriHealth New Jersey and AmeriHealth Pennsylvania COVID-19 webpages regularly for the latest news and updates. We will continue to evaluate member needs as the situation changes.

   The coverage is effective:

  • AmeriHealth Pennsylvania: October 22, 2020, through June 30, 2021.
  • AmeriHealth New Jersey: October 22, 2020, through the later of either June 30, 2021, or for a period of 90 days following the end of the state of emergency and public health emergency.

Learn more

Read more about the indications for use, coverage, dosage and administration recommendations, coding, and reimbursement in the News Articles posted on our Medical and Claim Payment Policy Portal: